Before the CDR, there were three steps. There was Health Canada, the Patented Medicines Prices Review Board, and then it went out to the provinces.
Now we have Health Canada reviews for safety and efficacy, Patented Medicines Prices Review Board reviews for the price, and the CDR reviews both of their studies and brings in some additional studies from the pharmaceutical industry or a manufacturer of the drug, we think, and then they make their recommendation.
Then the provinces continue to do the same reviews they used to do. They all had, if you remember when they set up the common drug review, promised to dismantle their review processes. They haven't. In fact, Ontario has increased and enhanced its drug review process. So we already have an example there where they're actually making their review processes at the provincial level stronger. B.C., in response to the Auditor General's report and a George Morfitt report from 2004, are also looking at other models for their drug review processes. In fact, they're looking to Oregon.
It seems to us that the common drug review was supposed to take away a layer, and it's not; in fact, it's just added another layer. So how is that not duplication and delay?